Start the New Year with an in vivo shuttle session on our syngeneic orthotopic glioblastoma mouse model

11 / 14 / 2018

To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-January 2019, in which a cost part will be supported by Explicyte.

Our validated syngeneic glioma mouse model is based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring. Model features as well as responsiveness to standard Temozolomide (TMZ) and immune checkpoint inhibitors (ICI) such as anti-PD1 antibody, makes it highly adapted for chemotherapeutic and immunotherapeutic candidate efficacy testing, either as single agents and/or in combinatorial regimen.
Start the New Year with an in vivo shuttle session on our syngeneic orthotopic glioblastoma mouse model

Orthotopic syngeneic GL261 glioblastoma model is responsive to TMZ and PD-1 blockade.

Mice were OT inoculated with GL261-Luc2 glioma cells and then treated with either Vehicle, TMZ or anti-PD1 antibody. Bioluminescence imaging was performed at Days 4, 14, and 21 after tumor cell inoculation. Survival was monitored overtime.

Start the New Year with an in vivo shuttle session on our syngeneic orthotopic glioblastoma mouse model


Common experimental settings:

  • Model / Strain: GL261-Luc2 glioblastoma / C57BL/6 mice
  • Readouts: Tumor growth (Bioluminescence imaging) / Body weight / Survival
  • Standard reference(s): TMZ or 𝛂PD1 monoclonal antibody – to be discussed with the Sponsor